CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 8 enrolled
Drug / intervention
Omadacycline Injectiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05515562
NCT05515562Phase 4Completed
CompareCT.gov

Effects of IV Omadacycline on Gut Microbiome

Wake Forest University Health Sciences·interventional·Posted Aug 25, 2022·Updated Mar 17, 2025

In Brief

A Phase 4 clinical trial evaluating Omadacycline Injection for Microbial Colonization. Completed, enrolled 8 participants across 1 site.

Detailed Summary

Given the clinical need to improve upon current antibiotic regimens for the treatment of C. difficile infection with a particular focus on the impact of therapies on gut microbiome, this study proposes to characterize the impact of Intravenous (IV) omadacycline on gut microbiome of healthy volunteers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMicrobial Colonization
CountriesUnited States
CollaboratorsUniversity of Houston, High Point University, Paratek Pharmaceuticals Inc

Timeline

Phase 4CompletedFinished
2023202420252026
First PostedAug 25, 2022
Enrollment StartMar 20, 2023
Primary CompletionJul 11, 2023
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 3.9 years ago

Interventions

Omadacycline Injectiondrug

All participants will receive Intravenous (IV) omadacycline